Genmab — April 2024

[E_L]

this may be useful for future
Congress Presentations - hint you are a US healthcare professional https://www.genmabmedicalaffairs.com/congress

[E_L]

new trial - A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/​Metastatic Head and Neck Cancer (OrigAMI-4) https://clinicaltrials.gov/study/NCT06385080

[ProinvestorNEWS]

Kort video..Der er kommet Q1-regnskab fra flere amerikanske selskaber. Bl.a. Tesla, IBM og Meta. Fedmeaktierne Novo Nordisk, Eli Lilly og Zealand Pharma falder efter kritik i USA af prissætningen på fedmeprodukter. Genmab falder også, efter to banker sænker kursmålet. https://www.proinvestor.com/boards/120115/

[Sukkeralf]

Regarding GEN1046 at ASCO - not impressed if its only a poster.

[E_L]

i was thinking the same to be honest...

[LP90]

Aktien har det godt nok svær

[LP90]

Godmorgen det gode ved aktien er faldet så meget er at den jo så også kan stige meget

[w]

jo længere ned den kommer,
jo flere aktier kan ledelsen ta' ud af markedet

[w]

Jeg faldt over Roei Mazor's kommentar på linkedin i forbindelse med FDA's mrd beslutning og hvad det kunne medføre for hexCD38: "Fascinating to see this asset in action".

[w]

tester han stoffet på sin klinik?

[JKY_VH]

Pas, men et eller andet har han jo tydeligvis set.

[E_L]

Roche Q1 '24 Lunsumio CHF16mn Columvi CHF 25mn

[E_L]

AbbVie Epkinly US $12, Intern. $15, Total $27. Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain
international territories

[E_L]

https://investors.abbvie.com/static-files/af510304-0bc1-4781-9090-b6c4a9be5edb

[E_L]

it's a bit difficult to get the exact total sales # out of this, i assume x2 for now. (Last year full 2023 Abbvie reported full year $31mn versus Genmab $64)

[E_L]

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rybrevant. PAPILLON -amivantamab in combination with carboplatin and
pemetrexed for the first-line treatment https://www.ema.europa.eu/en/medicines/human/variation/rybrevant

[E_L]

tisotumab vedotin submission in japan
https://genmab.co.jp/pressrelease/

[E_L]

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY https://www.amgen.com/newsroom/press-releases/2024/04/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency

[E_L]

In March 2024, Amgen submitted a marketing authorization application to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, a New Drug Submission (NDS) to Health Canada and an application to the Therapeutic Goods Administration (TGA) in Australia for teprotumumab. Teprotumumab is also under review by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

[Helge_LarsenPI-redaktør]

Godmorgen